115 related articles for article (PubMed ID: 2253676)
1. Pharmacokinetics of various single intravenous and oral doses of omeprazole.
Andersson T; Cederberg C; Regårdh CG; Skånberg I
Eur J Clin Pharmacol; 1990; 39(2):195-7. PubMed ID: 2253676
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses.
Regårdh CG; Andersson T; Lagerström PO; Lundborg P; Skånberg I
Ther Drug Monit; 1990 Mar; 12(2):163-72. PubMed ID: 2315973
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and absolute bioavailability of lansoprazole.
Gerloff J; Mignot A; Barth H; Heintze K
Eur J Clin Pharmacol; 1996; 50(4):293-7. PubMed ID: 8803522
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects.
Andersson T; Andrén K; Cederberg C; Lagerström PO; Lundborg P; Skånberg I
Br J Clin Pharmacol; 1990 May; 29(5):557-63. PubMed ID: 2350532
[TBL] [Abstract][Full Text] [Related]
5. Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19.
Chang M; Tybring G; Dahl ML; Götharson E; Sagar M; Seensalu R; Bertilsson L
Br J Clin Pharmacol; 1995 May; 39(5):511-8. PubMed ID: 7669487
[TBL] [Abstract][Full Text] [Related]
6. Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer.
Ching MS; Mihaly GW; Angus PW; Morgan DJ; Devenish-Meares S; Yeomans ND; Smallwood RA
Br J Clin Pharmacol; 1991 Feb; 31(2):166-70. PubMed ID: 2049231
[TBL] [Abstract][Full Text] [Related]
7. Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice.
Tassaneeyakul W; Vannaprasaht S; Yamazoe Y
Br J Clin Pharmacol; 2000 Feb; 49(2):139-44. PubMed ID: 10671908
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome.
Vinayek R; Amantea MA; Maton PN; Frucht H; Gardner JD; Jensen RT
Gastroenterology; 1991 Jul; 101(1):138-47. PubMed ID: 2044903
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic study of omeprazole in elderly healthy volunteers.
Landahl S; Andersson T; Larsson M; Lernfeldt B; Lundborg P; Regårdh CG; Sixt E; Skånberg I
Clin Pharmacokinet; 1992 Dec; 23(6):469-76. PubMed ID: 1458764
[TBL] [Abstract][Full Text] [Related]
10. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population.
Sohn DR; Kobayashi K; Chiba K; Lee KH; Shin SG; Ishizaki T
J Pharmacol Exp Ther; 1992 Sep; 262(3):1195-202. PubMed ID: 1527724
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects.
Setoyama T; Laurent A; Humphries T; Hasegawa J
Int J Clin Pharmacol Ther; 2005 Jan; 43(1):37-42. PubMed ID: 15704613
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability and efficacy of omeprazole given orally and by nasogastric tube.
Larson C; Cavuto NJ; Flockhart DA; Weinberg RB
Dig Dis Sci; 1996 Mar; 41(3):475-9. PubMed ID: 8617118
[TBL] [Abstract][Full Text] [Related]
13. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations.
Uno T; Niioka T; Hayakari M; Yasui-Furukori N; Sugawara K; Tateishi T
Eur J Clin Pharmacol; 2007 Feb; 63(2):143-9. PubMed ID: 17203292
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of fast disintegrating lansoprazole tablet in human subjects.
Iwasaki K; Yoshikawa Y; Shibata N; Takada K; Sakurai Y; Takagi N; Irie S; Nakamura K
Drug Metab Pharmacokinet; 2004 Jun; 19(3):227-35. PubMed ID: 15499190
[TBL] [Abstract][Full Text] [Related]
15. First-pass metabolism of omeprazole in rats.
Watanabe K; Furuno K; Eto K; Oishi R; Gomita Y
J Pharm Sci; 1994 Aug; 83(8):1131-4. PubMed ID: 7983597
[TBL] [Abstract][Full Text] [Related]
16. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects.
Flouvat B; Delhotal-Landes B; Cournot A; Dellatolas F
Br J Clin Pharmacol; 1993 Nov; 36(5):467-9. PubMed ID: 12959297
[TBL] [Abstract][Full Text] [Related]
17. Omeprazole: pharmacokinetics and metabolism in man.
Cederberg C; Andersson T; Skånberg I
Scand J Gastroenterol Suppl; 1989; 166():33-40; discussion 41-2. PubMed ID: 2690330
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients.
Cederberg C; Thomson AB; Mahachai V; Westin JA; Kirdeikis P; Fisher D; Zuk L; Marriage B
Gastroenterology; 1992 Sep; 103(3):913-8. PubMed ID: 1499942
[TBL] [Abstract][Full Text] [Related]
19. Variation in pharmacokinetics of omeprazole and its metabolites by gender and CYP2C19 genotype in Pakistani male and female subjects.
Nazir S; Iqbal Z; Ahmad L; Ahmad S
Pak J Pharm Sci; 2016 May; 29(3):887-94. PubMed ID: 27166533
[TBL] [Abstract][Full Text] [Related]
20. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.
Cho JY; Yu KS; Jang IJ; Yang BH; Shin SG; Yim DS
Br J Clin Pharmacol; 2002 Apr; 53(4):393-7. PubMed ID: 11966672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
